Connecta Therapeutics
Connecta Therapeutics is a clinical-stage biotechnology company developing CTH120, a neuroplasticity modulator designed to treat Fragile X Syndrome. The company focuses on neurodevelopmental and central nervous system disorders with no currently approved targeted therapies. Its pipeline includes disease-modifying approaches that have advanced into Phase IIa clinical trials for both adult and pediatric patient populations.
Biotechnology
Healthtech
Pharmaceuticals
Funding summary
- Total raised
- €1.7M
- Funding rounds
- 1
Investors in Connecta Therapeutics
Investors on record for Connecta Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Connecta Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors